Available as GENVOYA this four-drug combination of elvitegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), cobicistat, a CYP3A inhibitor, and emtricitabine and tenofovir alafenamide (TAF), both HIV- 1 nucleoside analog reverse transcriptase inhibitors (NRTIs) is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of GENVOYA.
|Generic name||elvitegravir+cobicistat+emtricitabine+tenofovir alafenamide|
|Also known as|
|Drug class||Fixed Dose Combinations|
|Pediatric dosing?||Available in doses suitable for children and/or young people.|
|Availability in Australia||Available on the Pharmaceutical Benefits Scheme (PBS) through S100 prescribers since|
This product contains multiple medicines which comprise a complete antiretroviral regimen for most people. However your doctor may prescribe other antiretrovirals to be taken in combination with elvitegravir+cobicistat+emtricitabine+tenofovir alafenamide if needed. Your doctor will advise you on the right combination of drugs to suit your circumstances.
The recommended dosage of GENVOYA is one tablet taken orally once daily with food.
Regardless of what you read on this website or elsewhere, you should always take your medications according to your doctor's instructions. If you're unsure, speak to your doctor or pharmacist.
All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.
Interactions with other drugs